1 Title: Point-of-care lung ultrasound predicts severe disease and death due to COVID-19: a

2 prospective cohort study.

- **3** Authors: Paul W. Blair, MD^{1,2*,**}, Trishul Siddharthan, MD^{3,4**}, Gigi Liu, MD⁵, Jiawei Bai,
- 4 PhD⁶, Joshua East, RPSGT⁴, Phabiola Herrera, MD³, Lalaine Anova, MS¹, Varun Mahadevan⁴,
- 5 Shakir Hossen, MBBS⁴, Stefanie Seo, BS⁷, Olamide Sonuga, BS⁷, Joshua Lawrence, BS⁷, Jillian
- 6 Peters, MD⁵, Andrea Cox, MD², Yukari C. Manabe, MD², Katherine Fenstermacher, PhD⁷,
- 7 Sophia Shea, MPH⁷, Richard E. Rothman, MD, PhD⁷, Bhakti Hansoti, MD⁷, Lauren Sauer, MS⁷,
- 8 Ciprian Crainiceanu, PhD⁶, Danielle V. Clark, PhD¹.
- 9 Affiliation:
- ¹The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD;
- 11 ²Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD
- ³Division of Pulmonary and Critical Care Medicine, University of Miami, Miami, FL
- ⁴Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of
- 14 Medicine, Baltimore, MD
- 15 ⁵Division of General Internal Medicine, Johns Hopkins University School of Medicine,
- 16 Baltimore, MD
- ⁶Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore MD
- ⁷Department of Emergency Medicine, Johns Hopkins University, Baltimore MD.
- 19
- 20 *Corresponding Author: Paul W. Blair, MD MSPH MHS. Henry M. Jackson Foundation for the
- 21 Advancement of Military Medicine. 6720A Rockledge Dr, Bethesda, MD 20817. E-mail:
- 22 pblair@aceso-sepsis.org
- 23 **Co-first authors.

- 24 Reprints: Reprints are not being ordered for this manuscript
- 25 Performance institution: Johns Hopkins University School of Medicine
- 26 Financial support: This project was supported by Joint Program Executive Office (JPEO-EB)
- 27 W911QY-20-9-0004 (2020 OTA) and the Johns Hopkins University School of Medicine
- 28 COVID-19 Research Fund.
- 29 Word count: 2,999
- 30 Abstract Word count: 296
- 31
- 32
- 52
- 33
- 34
- 35
- -
- 36
- 37
- 38
- 39
- 40
- ...
- 41
- 42
- 43
- 44
- 45
- 46

47 Abstract

48 Objective: The clinical utility of point-of-care lung ultrasound (LUS) for disease severity triage
49 of hospitalized patients with COVID-19 is unclear.

50 **Design:** Prospective cohort study

51 Setting: A large tertiary care center in Maryland, USA between April 2020 to September 2021.

52 **Patients:** Hospitalized adults (≥18 years of age) with positive SARS-CoV-2 RT-PCR results.

53 **Interventions:** None.

54 Measurements and Main Results: All patients were scanned using a standardized protocol

including 12 lung zones and followed to determine clinical outcomes until hospital discharge and

vital status at 28-days. Ultrasounds were independently reviewed for lung and pleural line

57 artifacts and abnormalities, and the mean Lung Ultrasound Score (ranging from 0 to 3) across

58 lung zones (mLUSS) was determined. The primary outcome was time to ICU-level care, defined

as high flow oxygen, noninvasive, or mechanical ventilation, within 28-days of the initial

60 ultrasound. Cox proportional hazards regression models adjusted for age and sex were fit for

61 mLUSS and each ultrasound covariate. A total of 264 participants were enrolled in the study; the

62 median age was 59 years and 114 (43.2) % of participants were female. The median mLUSS was

63 1 (interquartile range: 0.5 to 1.3). Following enrollment, 29 (11.0%) participants went on to

require ICU-level care and 14 (5.3%) subsequently died by 28 days. Each increase in mLUSS at

enrollment was associated with disease progression to ICU-level care (aHR = 3.63; 95% CI: 1.23

to 10.65) and 28-day mortality (aHR = 4.50; 95% CI: 1.52 to 13.31). Pleural line abnormalities

67 were independently associated with disease progression to ICU-level care (aHR = 18.86; CI:

68 1.57 to 226.09).

69	Conclusions: Participants with a mLUSS ≥ 1 or pleural line changes on LUS had an increased			
70	likelihood of subsequent requirement of high flow oxygen or greater. LUS is a promising tool for			
71	assessing risk of COVID-19 progression at the bedside.			
72	Key words: COVID-19, Ultrasonography, SARS-CoV-2, Survival Analysis, Cohort Studies			
73				
74				
75				
76				
77				
78				
79				
80				
81				
82				
83				
84				
85				
86				
87				
88				
89				
90				
91				

92 Introduction

93 Point-of-care lung ultrasound (LUS) has been used for the evaluation of a range of 94 cardiopulmonary conditions in emergency and critical care settings though, to date, 95 implementation protocols have varied across settings. LUS offers benefits over traditional 96 imaging modalities including portability, instantaneous results, lower costs, and lack of exposure 97 to ionizing radiation. LUS has been proposed as an essential tool in evaluating patients with 98 coronavirus disease 2019 (COVID-19) pneumonia to prevent nosocomial spread of disease.(1) 99 Ultrasound hardware can be cleaned easily and reduces the burden on personnel and resources 100 that would be required for traditional chest imaging. LUS may be able to identify patients at risk 101 for decompensation requiring higher level of care in resource-limited settings or in regions with 102 limited ICU capacity during a COVID-19 surge.

103

104 Despite the potential utility of LUS in COVID-19 management, standardized and evidence-based 105 clinical use has not been fully established. The most widely studied and reported findings are 106 based on the LUS score, originally developed in 2011 and used for assessment of aeration for 107 titration of positive end-expiratory pressure (PEEP) (2). This scoring system includes a 0 to 3 108 point grade per 6 lung zones totaled from each hemithorax (3). This has been adopted for 109 prognostication for non-COVID-19 acute respiratory distress syndrome (4) and was subsequently 110 evaluated as a part of candidate models for COVID-19 prognostication (5-9). Among individuals 111 with COVID-19, the LUS score has been associated with relevant chest CT findings and predicts 112 the extent of parenchymal disease as well as mortality.(5) However, modified scores have 113 limitations and have not been widely adopted. Modifications to scores had been based on early 114 anecdotal reports and resulted in multiple scoring systems without protocol standardization and

115	unclear generalizability. The LUS scores predicate on being able to sum all 12 zones, which can
116	be challenging to obtain in tenuous patients in prone position.

117

118 The aim of this study was to determine the association between baseline lung ultrasound findings 119 and the ultimate oxygen support requirements or death. We used a mean LUS (mLUSS) rather 120 than a sum to determine the utility of the original and most studied LUS score (2) for COVID-19 121 prognostication with the added flexibility to include less than 12 lung zones. We performed a 122 survival analysis with Cox regression mLUSS to determine risk of subsequently requiring ICU-123 level care (i.e., either high flow oxygen, noninvasive, or invasive ventilation) as a primary outcome. Secondary outcomes included ventilation plus 28-day death or 28-day death alone. We 124 125 hypothesized that the mLUSS would be associated with an increased risk of progression to 126 requiring ICU-level care.

127

128 Methods

129 We enrolled adults (≥18 years of age) who tested positive for SARS-CoV-2 on RT-PCR and 130 were admitted to Johns Hopkins Hospital in Baltimore, Maryland into a larger COVID-19 131 prospective cohort after verbal informed consent, between April 2020 to September 2021 as a 132 convenience sample. This protocol was approved by the Johns Hopkins University Institutional Review Board (IRB00245545). Participants were enrolled after admission throughout the 133 134 enrollment period or from the emergency department starting December 2020. After screening 135 2,270 patients, 723 participants enrolled into the master protocol, and 264 of these participants 136 had LUS performed as part of study procedures depending on LUS-trained research staff 137 availability.

138

139	LUS was standardized with 6-second clips from 12 lung zones with six lung zones on each side
140	as previously described.(10) All images were collected with a Lumify S4 phased array probe
141	(Philips, Amsterdam, Netherlands) using the application's lung scan settings. We employed a
142	standardized, point-of-care ultrasound (POCUS) research protocol to characterize lung
143	abnormalities in COVID-19. Study personnel received training by a clinician certified in critical
144	care ultrasonography and reviewed the initial ultrasound scanning sessions until operators were
145	proficient. Study personnel were subsequently masked to clinical information and recorded LUS
146	reads identifying and characterizing A lines (Figure 1A), B lines (Figure 1B and 1C), pleural
147	effusions (Figure 1D), pleural line abnormalities (Figure 1E), and consolidations (Figure 1F).
148	The pleural line was considered abnormal if it was irregular, fragmented, discontinuous, or ≥ 0.5
149	cm in thickness. Consolidations were required to be ≥ 0.25 cm in at least one dimension. While
150	hospitalized, study visits including lung ultrasound scans occurred on study days 0, 3, 7, and
151	weekly for up to 90 days. The first available scan was used for this analysis. Baseline
152	demographics, comorbid conditions, and oxygen requirements until discharge were determined
153	using the Hopkins Precision Medicine Analytics Platform (11), and duration of symptoms at
154	enrollment was determined through medical chart review. Date of death by 28 days from
155	enrollment was determined using the Precision Medicine Analytics Platform, medical chart
156	review, and review of the regional Maryland, Washington D.C, and Virginia health information
157	exchange (12).

158

As previously described (13), the LUS score was calculated for each zone with 1 point fordiscrete B lines, 2 points for coalescent B lines, and 3 points for lung consolidation. The mean

161 LUS score (mLUSS) ranges from 0 to 3, with a higher score signifying higher severity. The 162 mLUSS was calculated out of total available zones to include participants with missing zones. The Pearson correlation coefficient of the mLUSS between masked ultrasound clip readers was 163 164 determined for the participants that were available (61 consecutive patients or 23% of the 165 cohort). Participants were divided into severity groups at baseline based on severity at the time of 166 POCUS or peak severity prior to POCUS: on room air or nasal cannula supplemental oxygen 167 (moderate disease), on HFNC or noninvasive positive pressure ventilation (NIPPV) (moderately 168 severe), or on mechanical ventilation (severe disease). Summary statistics were performed by 169 comparing baseline demographics (i.e., sex, age, race, ethnicity, medical comorbidities), and 170 duration post symptom-onset between severity groups using Kruskal-Wallis tests. 171 172 Progression to ICU-level care was defined as newly requiring either high flow nasal cannula, 173 noninvasive ventilation, or mechanical ventilation during the hospitalization. To determine the 174 association between baseline LUS characteristics and future risk, this outcome was restricted to 175 study participants not requiring more than supplemental oxygen via low-flow nasal cannula at 176 baseline (among those with moderate disease at baseline, N=164) (Figure 2). Secondary 177 outcomes included 28-day mortality (all baseline severity groups, N=264) and 28-day 178 progression to mechanical ventilation or 28-day death (among those with moderate or 179 moderately severe disease, N=215) (Figure 2). A Kaplan-Meier plot was created to compare risk over time between those at the 25th and 75th mLUSS percentile. After checking the proportional 180 181 hazards assumption, Cox proportional hazards regression models were used to evaluate the 182 differences in risk of death and risk of death or subsequent mechanical ventilation plus 28-day 183 death as a function of baseline % of lung fields with A lines, % with B lines, % with

184	consolidations, % with pleural line abnormalities, % with pleural effusions, or the mLUSS.
185	Unadjusted analyses and analyses adjusting for age and biologic sex were performed. A
186	sensitivity analysis of the model including age, sex, and mLUSS covariates was performed
187	restricting the population to those with all 12 lung zones for each of the primary and secondary
188	outcomes. An additional sensitivity analysis was performed excluding 16 participants that were
189	asymptomatic. Data were analyzed in R (v4.0.2) and Stata, version 16.0 (StataCorp LLC,
190	College Station, TX, USA).

191

192 **Results**

193 Of 264 participants, the median age was 61 (interquartile range [IQR], 48 to 68 years) and 43.0% 194 (n = 114) were female (Table 1). The study participants were racially and ethnically diverse with 195 47.9% (n=127) of the population identified as black and 16.6% (n = 44) identified as Hispanic. 196 The median time from symptoms onset until ultrasound scan was 9.29 days (IQR, 5.15 to 14.31 197 days) and the median mLUSS at baseline was 1.00 (IQR, 0.50 – 1.30) overall. Comorbid illness 198 was common. The majority (74.2%) of participants had hypertension and 42.4% participants had 199 diabetes mellitus (Table 1). Diagnoses of congestive heart failure (33.0%) and chronic 200 obstructive pulmonary disease (36.4%) were also common. Most participants were overweight (median 30.0 kg/m²; IQR: 25.4 to 33.2). At baseline, 169 participants required only ambient 201 202 oxygen or nasal cannula supplemental oxygen, and an additional 46 participants (18.7%) were 203 requiring high flow nasal cannula (HFNC) or non-invasive positive pressure ventilation 204 (NIPPV). (Table 1) Lastly, 40 participants (16.3%) required mechanical ventilation at the time of 205 initial ultrasound scanning. During hospitalization, the most frequent treatments included 206 dexamethasone (63.6% of participants), remdesivir (50.0%), or tocilizumab (9.1%).

207

208 Baseline cross-sectional differences in POCUS findings by severity

- At enrollment, participants with severe illness were later in their course of illness (median: 15.79
- 210 days post symptom onset; IQR: 10.92 to 26.70 days) compared to those with moderately severe
- 211 (median: 9.29 days; IQR: 7.03 to 13.92 days), or moderate illness (median 7.38 days; IQR 4.08
- to 11.92 days) (Table 2). A lines were the most common finding among lung zones scanned
- 213 (median 75.0% of lung fields; IQR, 58.3 to 91.7%), with a stepwise decrease in proportion of
- lung zones affected in moderately severe disease (median 69.7%; IQR, 51.8 to 87.1%) followed
- by severe disease at enrollment (54.6%; IQR, 25.0 to 66.7%) (Table 2). B lines were more likely
- to be present among those with severe disease (median 75.0%; IQR, 60.0 to 100%) or
- 217 moderately severe disease (median 81.8%; IQR, 67.9 to 100%) compared to moderate cases
- 218 (median 57.1%; IQR, 27.3 to 75.0%). Similarly, participants requiring mechanical ventilation at
- enrollment had higher percent of pleural line abnormalities (median 25.0%; IQR, 9.1 to 50)
- compared to moderately severe (median 0.0%; 0.0 to 15.6%) or moderate (median 0.0%; IQR
- 221 0.0 to 16.7%) disease. The mLUSS was lower for moderate disease (median 0.83; IQR, 0.33 to
- 0.80) compared to a stepwise increase in moderately severe disease (median 1.11; IQR, 1.00 to
- 1.50) followed by severe critical disease (1.25; IQR, 1.00 to 1.67). The Pearson correlation
- coefficient of the mLUSS between readers was high at 0.77 among 61 participants with a an
- available matched masked LUS read (Supplemental Figure S1).

226

227 Risk of disease progression

228 When evaluating the 28-day risk of progression to severe COVID-19, multiple baseline POCUS

229 parameters were found to be associated with severity progression using Cox proportional hazards

230	regression. Each point increase in the mLUSS was associated with disease progression to ICU-
231	level care (aHR = 3.61; 95% CI: 1.27 to 10.22) and 28-day mortality (aHR = 3.10; 95% CI: 1.29
232	to 7.50), but not the composite outcome of ventilation or death ($aHR = 2.45$; 95% CI 0.81 to
233	11.02) (Figure 3 and Figure 4). Inference was unchanged when adjusting for total number of
234	available lung zones with an increased risk of progression to ICU-level care ($aHR = 3.80$; 95%
235	CI: 1.32 to 10.95) or death (aHR: 2.47; 95% CI: 1.10, 5.55), but not the composite outcome of
236	ventilation or death (aHR: 2.96; 95% CI: 0.80 to 11.01). Similarly, inference was unchanged
237	when excluding asymptomatic individuals with each increase in the mLUSS associated with risk
238	of progression to ICU-level care (aHR = 3.07; 95% CI: 1.04 to 9.07), death (aHR: 2.94; 95% CI:
239	1.21 to 7.15), but not ventilation or death together (aHR: 2.69; 95% CI: 0.66 to 11.05). Lastly,
240	when including days since symptom onset, there was an increased risk with each additional day
241	(aHR: 1.007; 95% CI: 1.001 to 1.01), but the risk associated with each increase in mLUSS was
242	similar (aHR: 3.86; 95% CI: 1.32 to 11.30) (Supplemental Table S1). There was no interaction
243	observed between duration of symptoms and mLUSS (p=0.48) (data not shown).
244	
245	Individual lung ultrasound characteristics were associated with disease progression. The
246	presence of any type of B line was not associated with an increased risk of progression to ICU-
247	level care (among those not on NIPPV, HFNC, or mechanical ventilation) (adjusted hazard ratio
248	[aHR] = 2.75; 95% confidence interval [CI], 0.45 to 16.71) but was associated with 28-day
249	mortality compared to those without any B lines (aHR = 13.43; 95% CI, 1.24 to 145.79) (Figure
250	4; Supplemental Table S1). Except for A lines, all studied individual POCUS parameters (i.e., B
251	lines, pleural line changes, consolidations, and pleural effusions) had an increased risk of
252	progression to ICU-level care, death, and death or ventilation but did not always meet statistical

253	significance. Accordingly, A lines, which are generally present in the absence of B lines, were
254	associated with a decreased risk of progression to ICU-level care (aHR 0.10; 95% CI, 0.02 to
255	0.69) and 28-day mortality (aHR = 0.10 ; 95% CI, 0.02- 0.63). Pleural abnormalities were
256	independently associated with mechanical ventilation plus death ($aHR = 21.78$; 95% CI, 1.30 to
257	365.95), and death (pleural line aHR = 20.93; 95% CI, 3.34 to 131.30).
258	
259	Discussion
260	We observed mLUSS and multiple individual LUS findings were associated with a subsequent
261	increased oxygen requirement or death in a prospective cohort. Our results support LUS to
262	identify hospitalized patients that may need a higher level of care or transport to centers with
263	ICU beds available. While many studies to date have used retrospective clinical data, we
264	conducted a prospective cohort study with standardized time points, probes, and protocols for
265	image acquisition. The findings of this study support the use of lung ultrasound as a clinical tool
266	that can improve triage by using individual POCUS abnormalities or mLUSS. Participants with
267	more A lines on LUS are less likely to clinically deteriorate and participants with irregular
268	pleural lines were more likely to have or to require higher levels of care. The mLUSS correlated
269	well between ultrasound readers and could be used for patients with difficult to scan lung zones.
270	These findings demonstrate the prognostic value of individual LUS findings or the mLUSS in
271	assessing anticipated disease severity trajectories of COVID-19 without necessarily requiring all
272	12 lung zones.
273	

Although there have been few large studies (5, 8), LUS has been shown to be associated with
radiographic and clinical severity among adults hospitalized with COVID-19. Nouvenne et al.

276 demonstrated B lines, pleural line irregularities and large parenchymal consolidations with 277 correlated with CT findings and oxygen saturation.(14) In a systematic review of 43 studies the 278 presence of focal, multifocal and/or confluent B lines and the presence of pleural irregularities 279 were common among individuals with COVID-19.(15) Mechanistically, the degree and 280 magnitude of LUS abnormalities throughout lung zones reflects the extent of lung disease and is 281 intuitively directly related to severe disease trajectories. In one of the largest studies to date with 282 matched CT scans, LUS compared to CT as a gold standard for severe COVD-19 had an area 283 under the curve of 0.78 (CI 95% 0.68–0.87; $p \square < \square 0.001$).(16) Rubio-Garcia and colleagues 284 examined the LUS among 130 patients with COVID 19 and demonstrated an increased risk of 285 mortality among individuals with a high modified LUS score (HR 5.25, 0.84–32.84) (9). The 286 investigators however did not describe individual features of the LUS such as A lines, B lines and pleural disease and used a high cutoff to optimize sensitivity (9). While other studies have 287 288 generally used a sum of all 12 lung zones (5, 8, 9, 17), our study found the risk estimates were 289 unchanged when some lung fields were not obtainable due to clinical instability. Our study is 290 consistent with prior publications and provides evidence that LUS can prognosticate hospitalized 291 patients using available lung zones.

292

Adoption of LUS has varied in hospital settings largely a result of lack of familiarity as well as
difference in approaches, techniques, and nomenclature (18). However, research personnel in our
study were taught lung ultrasound using standardized protocols without prior experience.
Ultrasound images were overread by multiple reviewers and correlated well. Most ultrasound
operators were research coordinators who had no experience with ultrasound scanning prior to
training for this study. This provided standardization of scans and reduced bias related to direct

299 performance by medical caregivers. This suggests that LUS scanning could be expanded to non-300 clinicians, including but not limited to nursing staff, respiratory therapists, or medics in the field. 301 For example, respiratory therapists or nursing staff could routinely perform LUS scans to obtain 302 and document this valuable information, similar to lung auscultation performed at some centers. 303 Alternatively, ultrasound technicians would be well-equipped to perform LUS scans with a 304 standardized read by radiology. While the value of immediate information to a performing 305 clinician should not be ignored or undervalued, extending the expertise of LUS performance to 306 additional healthcare workers would be more scalable than LUS by clinicians alone. 307 308 Biomarker and therapeutic research has identified the importance of phase of disease as indicated 309 by duration of symptoms (19). However, inference was unchanged after adjusting for duration of 310 symptoms or interaction with duration in our Cox regression models. POCUS results appeared to 311 be generalizable regardless of adjustment for days since symptom onset for determining risk of 312 decompensation towards ICU-level care. Change in LUS findings were not evaluated here due to 313 a limited sample size of repeat time events (data not shown), but studies are ongoing to evaluate 314 longitudinal LUS for estimating risk of severe disease and treatment response. 315

There were limitations to the present study. First, not all participants were enrolled prior to admission, and as this was a hospital-based protocol, generally had a minimum requirement of oxygen. Patients were not always enrolled on the day of admission which may have diminished the effect size of differences in POCUS findings. Additionally, those hospitalized with incidental asymptomatic SARS-CoV-2 infection may be less comparable to those with moderate severity, but a sensitivity analysis was performed and inference about risk was unchanged. These factors

322	led to sample size limitations in some of the survival analyses leading to wide confidence			
323	intervals, but the qualitative inference was consistent across outcomes and remains important.			
324	Further work is ongoing in ambulatory settings and additional sites with standardized follow-up			
325	to improve our understanding of the external validity and diagnostic accuracy among additional			
326	populations including non-hospitalized individuals with COVID 19. Lastly, while the mLUSS			
327	provide valuable prognostic information, additional lung ultrasound features such as			
328	consolidations or pleural line changes appear to be useful prognostic findings and should be			
329	evaluated for incorporation into models with subsequent validation. Future research with			
330	machine learning and unsupervised approaches can help optimize LUS for clinical use.			
331				
332	Conclusion			
333	Individual LUS findings and the mLUSS across available lung zones on lung POCUS are			
334	associated with ultimate oxygen requirement or death, independent of duration of illness among			
335	hospitalized patients.			
336				
337	Acknowledgments: We thank the participants within the CCPSEI cohort study.			
338	Potential conflicts of interest: Y.C.M. receives research funding from Becton Dickinson,			
339	Quanterix, and Hologic and receives funding support to Johns Hopkins University from			
340	miDiagnostics.			
341	Conferences: This analysis has not been previously presented.			
342	Disclaimer: The contents of this article are the sole responsibility of the authors and do not			
343	necessarily reflect the views, assertions, opinions, or policies of the Henry M. Jackson			
344	Foundation for the Advancement of Military Medicine, Inc., the U.S. Department of Defense, the			

345	U.S. government, or any other government or agency. Mention of trade names, commercial				
346	products, or organizations does not imply endorsement by the U.S. government. The				
347	investigators have adhered to the policies for protection of human subjects as prescribed in 45				
348	CFR 46.				
349					
350	References				
351	1.	Buonsenso D, Pata D, Chiaretti A: COVID-19 outbreak: less stethoscope, more			
352	ultrasound. Lancet Respir Med 2020				
353	2.	Bouhemad B, Brisson H, Le-Guen M, et al: Bedside ultrasound assessment of positive			
354	end-expiratory pressure-induced lung recruitment. Am J Respir Crit Care Med 2011; 183(3):341-				
355	347				
356	3.	Ampuero J, Sánchez Y, García-Lozano MR, et al: Impact of liver injury on the severity			
357	of COVID-19: a systematic review with meta-analysis. Rev Esp Enferm Dig 2021; 113(2):125-				
358	135				
359	4.	Zhao Z, Jiang L, Xi X, et al: Prognostic value of extravascular lung water assessed with			
360	lung ultrasound score by chest sonography in patients with acute respiratory distress syndrome.				
361	BMC I	Pulm Med 2015; 15:98			
362	5.	de Alencar JCG, Marchini JFM, Marino LO, et al: Lung ultrasound score predicts			
363	outcon	nes in COVID-19 patients admitted to the emergency department. Ann Intensive Care			
364	2021; 11(1):6				
365	6.	Brahier T, Meuwly JY, Pantet O, et al: Lung ultrasonography for risk stratification in			
366	patients with COVID-19: a prospective observational cohort study. Clin Infect Dis 2020				

- 367 7. Alharthy A, Faqihi F, Abuhamdah M, et al: Prospective Longitudinal Evaluation of
- 368 Point-of-Care Lung Ultrasound in Critically Ill Patients With Severe COVID-19 Pneumonia. J
- 369 Ultrasound Med 2020
- 370 8. Ji L, Cao C, Gao Y, et al: Prognostic value of bedside lung ultrasound score in patients
- 371 with COVID-19. *Crit Care* 2020; 24(1):700
- 9. Rubio-Gracia J, Giménez-López I, Garcés-Horna V, et al: Point-of-care lung ultrasound
- assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective
- 374 noninterventional study. *Eur Respir J* 2021; 58(3)
- 375 10. Soldati G, Smargiassi A, Inchingolo R, et al: Proposal for International Standardization
- of the Use of Lung Ultrasound for Patients With COVID-19: A Simple, Quantitative,
- 377 Reproducible Method. J Ultrasound Med 2020; 39(7):1413-1419
- 11. inHealth JH: PMAP: The Johns Hopkins Precision Medicine Analytics Platform.
- 379 Available at: <u>https://pm.jh.edu/</u>. Accessed December 30, 2021
- 380 12. Gryczynski J, Nordeck CD, Martin RD, et al: Leveraging health information exchange
- 381 for clinical research: Extreme underreporting of hospital service utilization among patients with
- 382 substance use disorders. *Drug Alcohol Depend* 2020; 212:107992
- 383 13. Soummer A, Perbet S, Brisson H, et al: Ultrasound assessment of lung aeration loss
- during a successful weaning trial predicts postextubation distress*. *Crit Care Med* 2012;
- **385** 40(7):2064-2072
- 14. Nouvenne A, Zani MD, Milanese G, et al: Lung Ultrasound in COVID-19 Pneumonia:
- 387 Correlations with Chest CT on Hospital admission. *Respiration* 2020; 99(7):617-624
- 388 15. Peixoto AO, Costa RM, Uzun R, et al: Applicability of lung ultrasound in COVID-19
- diagnosis and evaluation of the disease progression: A systematic review. *Pulmonology* 2021

- 390 16. Zieleskiewicz L, Markarian T, Lopez A, et al: Comparative study of lung ultrasound and
- 391 chest computed tomography scan in the assessment of severity of confirmed COVID-19
- 392 pneumonia. Intensive Care Med 2020; 46(9):1707-1713
- 393 17. Lichter Y, Topilsky Y, Taieb P, et al: Lung ultrasound predicts clinical course and
- 394 outcomes in COVID-19 patients. *Intensive Care Med* 2020; 46(10):1873-1883
- 395 18. Volpicelli G, Elbarbary M, Blaivas M, et al: International evidence-based
- recommendations for point-of-care lung ultrasound. *Intensive Care Med* 2012; 38(4):577-591
- 397 19. Datta SD, Talwar A, Lee JT: A Proposed Framework and Timeline of the Spectrum of
- 398 Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health
- 399 Implications. *JAMA* 2020; 324(22):2251-2252
- 400
- 401
- 402 Figure legends.
- 403 Figure 1. Lung ultrasound characteristics. 1A: A lines (arrows) are shown indicating normal
- 404 lung aeration; 1B: discrete B lines (arrows), implicating subpleural interstitial edema; 1C: a
- 405 coalesced B line (arrow); 1D: a small pleural effusion (arrow); 1E: fragmented pleural line
- 406 (arrow); 1F: a subpleural consolidation (arrow).
- **Figure 2.** Flow diagram of enrollments and total participants included in survival analyses.
- **Figure 3.** Kaplan-Meier time to progression by 75th percentile (1.3) vs 25th percentile (0.5)
- 409 mLUSS scores from time of lung ultrasound scan.
- 410 Figure 4. Forest Plot of hazard ratios of LUS parameters from individually fit models adjusting
- 411 for age and sex for progression to severe disease.
- 412



S4-1

Prese Lung

Power -0.3 dB





ſ

F



Α

sr2l









- mLUSS = 0.5 - mLUSS = 1.3 - Unadjusted

Progression to ICU-level care

А

С

Progression to death



Characteristic Total (N=264) Age —years, median (IQR) 58.56 (48.75, 68.00) Female — no. (%) 114 (43.18) Race — no. (%) Asian 7 (2.65) Black 126 (47.73) White 80 (30.30) Other 49 (18.46) Ethnicity — no. (%) Hispanic 44 (16.67) **Non-Hispanic** 220 (83.33) Smoking — no. (%) Never 149 (56.44%) Current 23 (8.71%) Former 80 (30.30%) Median BMI — kg/m², median (IQR) 30.00 (25.4, 33.2) Comorbidities — no. (%) Cancer 25 (9.5) **Congestive heart failure** 87 (33.0) COPD 96 (36.4) **Diabetes** 112 (42.4) Hypertension 196 (74.2) **HIV/AIDS** 12 (4.6) Liver Disease 54 (20.5) Symptoms onset until LUS Scan — days, median (IQR) 9.29 (5.2, 14.3) Total lung zones scanned — median (IQR) 9 (7, 12) mLUS Score - median (IQR) 1.00 (0.50, 1.30) A-line lung fields — %, median (IQR) 0.75 (0.58, 0.92) B-line lung fields — %, median (IQR) 0.67 (0.38, 0.84) Pleural Line abnormality lung fields — %, median (IQR) 0.00 (0.00, 0.18)

Table 1. Participant baseline demographics.

NIPPV: Non-invasive positive pressure ventilation; mLUS: mean lung ultrasound score

Oxygen requirement severity at baseline scan	Moderate: Ambient or low-flow nasal cannula (N=169)	Moderately Severe: High flow nasal cannula or NIPPV (N=46)	Severe: Ventilation at LUS (N=49)	p-value†
Age—years, median (IQR)	57.8 (46.00, 68.00)	61.30 (55.25, 69.00)	58.57 (53.00, 67.00)	< 0.001
Female — no. (%)	84 (49.70)	18 (39.13)	12 (24.49)	0.006
Race — no. (%)				0.584
Asian	1 (0.59)	5 (10.87)	1 (2.04)	
Black	92 (54.44)	18 (39.13)	16 (32.65)	
White	49 (28.99)	15 (32.61)	16 (32.65)	
Other	26 (15.38)	8 (17.39)	15 (30.61)	
Ethnicity — no. (%)				0.445
Hispanic	25 (14.79)	8 (17.39)	11 (22.44)	
Non-Hispanic	144 (85.21)	38 (82.61)	38 (77.55)	
Median BMI — kg/m ² , median (IQR)	29.03 (24.18, 32.88)	31.22 (26.75, 33.17)	31.83 (27.05, 34.58)	0.054
Comorbidities — no. (%)				
Cancer	20 (11.83)	0 (0.00)	5 (10.20)	0.051
Congestive heart	50 (29.59)	15 (32.61)	22 (44.90)	0.141
failure	65 (38.46)	15 (32.61)	16 (32.65)	0.620
COPD	125 (73.96)	35 (76.09)	36 (73.47)	0.957
Hypertension	32 (18.93)	11 (23.91)	11 (22.45)	0.720
Liver Disease	69 (40.83)	19 (41.30)	24 (48.98)	0.605
Diabetes HIV/AIDS	8 (4.73)	4 (8.70)	0 (0.00)	0.126
Symptoms onset until LUS Scan — days, median (IQR)	7.38 (4.08, 11.92)	9.29 (7.03, 13.92)	15.79 (10.92, 26.70)	<0.001
mLUS Score — median (IQR)	0.83 (0.33, 0.80)	1.11 (1.00, 1.50)	1.25 (1.00, 1.67)	<0.001
A-line lung fields —%, median (IQR)	0.86 (0.67, 1.00)	0.697 (0.518, 0.87)	0.546 (0.25, 0.67)	<0.001
B-line lung fields — %, median (IQR)	0.57 (0.27, 0.75)	0.82 (0.68, 1.00)	0.750 (0.60, 1.00)	<0.001
Pleural Line abnormality lung fields — %, median (IQR)	0.00 (0.00, 0.17)	0.000 (0.00, 0.16)	0.25 (0. 09, 0.50)	<0.001

Table 2. Cross-sectional differences in lung ultrasound findings by severity at baseline.

NIPPV: Non-invasive positive pressure ventilation; mLUS: mean lung ultrasound score †Kruskal-Wallis test by ranks